Established in 1925, Croda is the name behind high performance ingredients and technologies in some of the world’s biggest and... View Article
Author Archives for Adeline Chauvigné
New member | Croda – Smart Science to Improve Lives
19 September 2025Established in 1925, Croda is the name behind high performance ingredients and technologies in some of the world’s biggest and... View Article
New member | Biowest – The serum specialist
Based in Nuaillé (Cholet), Biowest was founded in 1987. The company launched its activity by processing and distributing animal sera... View Article
New member | Biowest – The serum specialist
19 September 2025Based in Nuaillé (Cholet), Biowest was founded in 1987. The company launched its activity by processing and distributing animal sera... View Article
Phase 3 Clinical Trial of Tedopi®: OSE Immunotherapeutics Announces Positive Top-Line Results for Step-1 of its trial ‘Atalante 1’ in Non-Small Cell Lung Cancer
• Step-1 primary endpoint met: 12-month survival rate in Tedopi® treated patients; • Complete analysis of Step-1 results and further... View Article
Phase 3 Clinical Trial of Tedopi®: OSE Immunotherapeutics Announces Positive Top-Line Results for Step-1 of its trial ‘Atalante 1’ in Non-Small Cell Lung Cancer
19 September 2025• Step-1 primary endpoint met: 12-month survival rate in Tedopi® treated patients; • Complete analysis of Step-1 results and further... View Article
OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement for IL-7R Antagonist OSE-127 in Autoimmune Diseases
Under this amendment, OSE Immunotherapeutics will receive a €5 million milestone payment at the start of the Sjögren’s Phase 2... View Article
OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement for IL-7R Antagonist OSE-127 in Autoimmune Diseases
19 September 2025Under this amendment, OSE Immunotherapeutics will receive a €5 million milestone payment at the start of the Sjögren’s Phase 2... View Article
GRAFTYS ADDS A NEW DISTRIBUTION PARTNERSHIP IN THE US TERRITORY
GRAFTYS SA (“Graftys”), a global leader in resorbable bone cements, today announces a new distribution agreement for its bestselling... View Article
GRAFTYS ADDS A NEW DISTRIBUTION PARTNERSHIP IN THE US TERRITORY
19 September 2025GRAFTYS SA (“Graftys”), a global leader in resorbable bone cements, today announces a new distribution agreement for its bestselling... View Article
NEW MEMBER | WELIOM
ASSESS, ADVISE, STEER WELIOM is emerging as a partner in the reconfiguration of healthcare institutions, deploying healthcare stakeholders, recognised experts... View Article
NEW MEMBER | WELIOM
19 September 2025ASSESS, ADVISE, STEER WELIOM is emerging as a partner in the reconfiguration of healthcare institutions, deploying healthcare stakeholders, recognised experts... View Article
NEW MEMBER | NUCLEOPOLIS
NUCLEOPOLIS, THE NORMANDIE ENERGIES NUCLEAR CLUSTER Nucleopolis is the Normandie Énergies nuclear cluster, a major player in the Normandy energy... View Article
NEW MEMBER | NUCLEOPOLIS
19 September 2025NUCLEOPOLIS, THE NORMANDIE ENERGIES NUCLEAR CLUSTER Nucleopolis is the Normandie Énergies nuclear cluster, a major player in the Normandy energy... View Article
NEW MEMBER | GUTY
THE SMART ASSISTANT PROVIDING CARE AND SUPPORT SERVICES FOR GASTROINTESTINAL DISORDERS AND DIGESTIVE DISEASES Guty is the leading smart solution... View Article
NEW MEMBER | GUTY
19 September 2025THE SMART ASSISTANT PROVIDING CARE AND SUPPORT SERVICES FOR GASTROINTESTINAL DISORDERS AND DIGESTIVE DISEASES Guty is the leading smart solution... View Article
NEW MEMBER | ADWST
THERAPEUTIC WATER DEVELOPMENT NATARYS was created in 2007 based on the strongly held belief that providing people with access to... View Article
NEW MEMBER | ADWST
19 September 2025THERAPEUTIC WATER DEVELOPMENT NATARYS was created in 2007 based on the strongly held belief that providing people with access to... View Article
ABOLERIS PHARMA – CONTROLLING AUTOIMMUNE DISEASES AND TRANSPLANT REJECTIONS
ABOLERIS PHARMA, AN EMERGING COMPANY IN THE FIELD OF IMMUNOTHERAPY RESEARCH ESTABLISHED ON 28th NOVEMBER 2019, DEVELOPS PROPRIETARY MOLECULES THAT... View Article
ABOLERIS PHARMA – CONTROLLING AUTOIMMUNE DISEASES AND TRANSPLANT REJECTIONS
19 September 2025ABOLERIS PHARMA, AN EMERGING COMPANY IN THE FIELD OF IMMUNOTHERAPY RESEARCH ESTABLISHED ON 28th NOVEMBER 2019, DEVELOPS PROPRIETARY MOLECULES THAT... View Article